Skip to main content

Advertisement

Log in

Comparison of PAX6 and PAX8 as Immunohistochemical Markers for Pancreatic Neuroendocrine Tumors

  • Published:
Endocrine Pathology Aims and scope Submit manuscript

Abstract

To compare the utility of PAX6 and PAX8 as immunohistochemical markers for neuroendocrine tumors (NETs) of pancreatic origin, we performed PAX6 and PAX8 immunostains on 178 NETs, including 110 primary NETs (26 pancreatic, 10 gastric, 12 duodenal, 22 jejuno-ileal, 10 rectal, 30 pulmonary) and 68 NETs metastatic to the liver (24 pancreatic, 1 duodenal, 37 jejuno-ileal, 1 rectal, 5 pulmonary). Among primary NETs, PAX6 and PAX8 were positive in 65 % (17/26) and 73 % (19/26) of pancreatic, 0 % (0/10) and 10 % (1/10) of gastric, 92 % (11/12) and 92 % (11/12) of duodenal, 0 % (0/22) and 0 % (0/22) of jejuno-ileal, 90 % (9/10) and 80 % (8/10) of rectal, and 0 % (0/30) and 23 % (7/30) of pulmonary NETs, respectively. PAX6 and PAX8 positivity was seen in 46 % (11/24) and 50 % (12/24) of metastatic pancreatic NETs to the liver, respectively. None of the nonpancreatic NETs metastatic to the liver were immunoreactive for either PAX6 or PAX8. PAX6 showed a slightly but statistically significant higher specificity for pancreatic NETs than did PAX8 (P = 0.039), while the sensitivities were similar (P = 0.51). PAX6 had the additional advantages over PAX8 of not exhibiting nonspecific cytoplasmic staining of tumor cells and only infrequently staining background lymphocytes. Since rectal NETs rarely present with metastatic disease, positive staining of a metastatic NET of unknown primary origin for PAX6 and/or PAX8 favors a pancreatic or duodenal origin. This information may be helpful in directing further diagnostic studies to identify the primary site of the metastatic tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Long KB, Srivastava A, Hirsch MS, Hornick JL. PAX8 expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol 2010; 34:723–729.

    Article  PubMed  Google Scholar 

  2. Haynes CM, Sangoi AR, Pai RK. PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens. Cancer Cytopathol 2011; 119:193–201.

    Article  PubMed  Google Scholar 

  3. Sangoi AR, Ohgami RS, Pai RK, Beck AH, McKenney JK, Pai RK. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol 2011; 24:412–424.

    Article  CAS  PubMed  Google Scholar 

  4. Koo J, Mertens RB, Mirocha JM, Wang HL, Dhall D. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin. Mod Pathol 2012; 25:893–901.

    Article  CAS  PubMed  Google Scholar 

  5. Lorenzo PI, Jimenez Moreno CM, Delgado I, Cobo-Vuilleumier N, Meier R, Gomez-Izquierdo L, Berney T, Garcia-Carbonero R, Rojas A, Gauthier BR. Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors. Histochem Cell Biol. 2011; 36:595–607.

    Article  Google Scholar 

  6. Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). WHO Classification of Tumors of the Digestive System. IARC Press, Lyon, 2010, pp 13–14.

    Google Scholar 

  7. Moreno CM, Lorenzo PI, Delgado I, Cobo-Vuilleumier N, Gomez-Izquierdo L, Garcia-Carbonero R, Rojas A, Gauthier BR. Pax8 detection in well-differentiated pancreatic endocrine tumors: how reliable is it? Am J Surg Pathol. 2011; 35:1906–8.

    Article  PubMed  Google Scholar 

  8. St-Onge L, Sosa-Pineda B, Chowdhury K, Mansouri A, Gruss P. Pax6 is required for differentiation of glucagon-producing alpha-cells in mouse pancreas. Nature. 1997; 387:406–9.

    Article  CAS  PubMed  Google Scholar 

  9. Sander M, Neubüser A, Kalamaras J, Ee HC, Martin GR, German MS. Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development. Genes Dev. 1997; 11:1662–73.

    Article  CAS  PubMed  Google Scholar 

  10. Gosmain Y, Katz LS, Masson MH, Cheyssac C, Poisson C, Philippe J. Pax6 is crucial for β-cell function, insulin biosynthesis, and glucose-induced insulin secretion. Mol Endocrinol. 2012; 26:696–709.

    Article  CAS  PubMed  Google Scholar 

  11. Gosmain Y, Cheyssac C, Heddad Masson M, Dibner C, Philippe J. Glucagon gene expression in the endocrine pancreas: the role of the transcription factor Pax6 in α-cell differentiation, glucagon biosynthesis and secretion. Diabetes Obes Metab. 2011; 13 Suppl 1:31–8.

    Article  CAS  PubMed  Google Scholar 

  12. Larsson LI, St-Onge L, Hougaard DM, Sosa-Pineda B and Gruss P. Pax4 and 6 regulate gastrointestinal endocrine cell development. Mech Dev 1998; 79: 153–9.

    Article  CAS  PubMed  Google Scholar 

  13. Hill ME, Asa SL, Drucker DJ. Essential requirement for Pax6 in control of enteroendocrine proglucagon gene transcription. Mol Endocrinol. 1999; 13:1474–86.

    Article  CAS  PubMed  Google Scholar 

  14. Zhang L, Smyrk TC, Oliveira AM, Lohse CM, Zhang S, Johnson MR, Lloyd RV. KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers. Am J Surg Pathol. 2009; 33:1562–9.

    Article  PubMed  Google Scholar 

  15. Moretti L, Medeiro S, Kunkalla K, Williams MD, Singh RR, Vega F. N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. Mod Pathol. 2012; 25:231–6.

    CAS  PubMed  Google Scholar 

  16. Song J, Li M, Tretiakova M, Salgia R, Cagle PT, Husain AN. Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung. Arch Pathol Lab Med. 2010; 134:1702–5.

    PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Jin-Ping Lai or Deepti Dhall.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lai, JP., Mertens, R.B., Mirocha, J. et al. Comparison of PAX6 and PAX8 as Immunohistochemical Markers for Pancreatic Neuroendocrine Tumors. Endocr Pathol 26, 54–62 (2015). https://doi.org/10.1007/s12022-014-9346-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12022-014-9346-3

Keywords

Navigation